Table 4 Change rate in each marker after treatment
From: The effect of dapagliflozin treatment on epicardial adipose tissue volume
|  | Dapagliflozin (n = 20) | Conventional therapy (n = 20) | p value, dapagliflozin vs. conventional |
|---|---|---|---|
Δ body weight (kg) | − 2.9 ± 3.4** | 0.2 ± 2.4 | 0.01 |
Lipid profile | |||
 ΔLDL (mg/dl) | 6.0 ± 26.5 | − 1.0 ± 13.7 | 0.41 |
 ΔTG (mg/dl) | − 33.4 ± 66.2* | 3.2 ± 19.0 | 0.07 |
 ΔHDL (mg/dl) | 5.1 ± 15.2 | − 0.7 ± 4.8 | 0.21 |
 ΔTG/HDL | − 0.8 ± 1.7** | 0.2 ± 0.8 | 0.06 |
Glycemic marker | |||
 ΔHbA1c (%) | − 0.41 ± 0.21** | − 0.19 ± 0.25 | 0.22 |
 ΔHOMA-IR | − 0.99 ± 1.90** | − 0.42 ± 0.86* | 0.64 |
 ΔiHOMA2%S | 65.7 ± 70.9** | 42.2 ± 61.1 | 0.36 |
ΔBNP (pg/ml) | − 24 ± 83 | − 12 ± 54 | 0.68 |
ΔAlb/Cre (mg/g·CRE) | − 3.8 ± 29.6 | 8.7 ± 43.2 | 0.38 |